Why Use Humanized Mouse Models for Translational Studies in Inflammatory Disorders?

The drug development process strongly relies on the predictivity of preclinical mouse modeling. Humanized mouse models, i.e., mouse models that recapitulate human components are therefore highly valuable translational tools.

In this webinar, the featured speakers will showcase drug testing in humanized mouse models in two therapeutic areas: food allergy and inflammatory bowel diseases (IBD):

1. Inflammatory bowel diseases, which include ulcerative colitis and Crohn’s disease, are characterized by a chronic inflammation of the intestinal tract. Even though conventional treatments such as immune modulators might improve the symptoms, a high number of patients do not respond to the available treatments. In the first part of the webinar, Dr. Ho Wang Yin, PhD, CIO will show how humanized mouse models help develop new therapies for IBD. She will provide an overview of chemically induced models of acute colitis (DSS and TNBS), the pros and cons of each model and a summary of typical study design.

2. Peanut allergy affects up to two percent of the pediatric population and is a high unmet medical need as peanut ingestion is the most common cause of food induced anaphylaxis in the US. Oral immunotherapy, the only US Food and Drug Administration (FDA) approved therapy, is lengthy and carries the risk of serious side effects. In the second part of the webinar, Dr. Wuillemin will demonstrate the efficacy of MY006, a passive immunotherapy developed thanks to Mabylon’s unique antibody discovery platform, for the treatment of peanut allergy in humanized mouse models.

Register for this webinar to explore the importance of using humanized mouse models for translational studies in inflammatory disorders.

Speakers

Natascha Wuillemin, PhD, Executive Vice President Immunology at Mabylon AG

Dr. Natascha Wuillemin joined Mabylon in August 2015. She has a master’s degree in pharmaceutical sciences (ETH Zurich) and a PhD in immunology (University of Bern). During her PhD and postdoctoral training, she has established in vitro models for better understanding of HLA-related drug hypersensitivity reactions and gained expertise in in vitro allergy research.

Message Presenter

Kiave-Yune Ho Wang Yin, PhD, Director of Innovation and Business development at TransCure bioServices

Kiave-Yune Ho Wang Yin, PhD, Director of Innovation and Business development. Kiave Ho Wang Yin holds a PhD in immunology/oncology from the Paris 7 University (France). She worked for five years in the Center of Cardiovascular Research (Paris) as a scientist in the field of inflammation and angiogenesis. She has published more than 10 papers in peer-reviewed international journals in oncology and inflammation. She is a highly experienced scientist in R&D research and in vivo pharmacology preclinical mouse models and joined the TransCure bioServices in 2016.

Message Presenter